01187-A: The Role of mTOR in Canine Lymphoma

Grant Status: Closed

Grant Amount: $12,900.68
Dr. Michael S. Kent, DVM, University of California, Davis
July 1, 2008 - March 31, 2009
Breed(s): -All Dogs
Research Program Area: Treatment

Project Summary

Lymphoma is the most common malignant tumor in the dog. It is a highly aggressive cancer and while most dogs achieve remission with chemotherapy treatment the lymphoma usually returns within a year and eventually leads to their death. The AKT/mTOR pathway is turned on in many forms of human cancer, including lymphosarcoma and other hematologic malignancies. In this study we have identified that the AKT/mTOR pathway is present and active in four canine lymphoma cell lines. Further we have found that we can slow cellular proliferation by treating the cells with rapamycin, which inhibits this pathway. We have also collected lymph node aspirates from dogs with lymphoma and also found that this pathway is active in dogs with lymphoma. While this work is ongoing, it supports that use of mTOR inhibitors in the reatment of lymphoma.

Publication(s)

9/22/09 - None at this time. Publication Planned

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $50
  • $100
  • $250
  • $1000
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2016 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software